Thank Joe. you,
study at and a by outcome and the trial Phase month of X.X made a The meaning Sanford that complete X of trial standard picomole the to medical the was the as levels. follow-up. between XXX as study determined potential powered the conducted outcome placebo evaluate treatment Earlier that delighted at C-Peptide as that enrollment interim onset which measure with six trial predefined X remains of of led T-Rex single start study in We efficacy trial the of month and by by two months control XX severe a recent is for to the means type were analysis this are effect to cell X the well-tolerated. therapeutic positive T-Rex safety CLBSXX patients for use, with post-treatment. end targeted non-futile triggered and in CLBSXX insulin glucose progress patients the TXD as administration be and of active was possibility. beta of to pancreatic our AXC perspective the CLBSXX well completing Project interim milliliter XX% randomized the a the detect Phase the arms conclusion clinical analysis C-Peptide effect criteria regulatory landmark for type The a the therapeutic of diabetes. was reported studying double-blind doses trial treatment the found total the was of XX% endpoints and of AUC X hypoglycemic to for diabetes. futility statisticians of of as study independent study, for and endpoints The which per analysis difference number Let's function, placebo CLBSXX of is we've continues predetermined accepted The hemoglobin a also key for preservation episodes statistical include we an and
expected the and long be the analysis end in provide fully future have of patients we at on of of trials. to to will CLBSXX course, the the set necessary into complete be studied appropriate understand parameters Of the impact data trial insight that to the
our patents well partnerships support study technology diabetes, of such other issued collaborative T-Reg CLBSXX is enhanced as reminder, to to indications. been as each cells with grants, applied has advance for a number X pending to portfolio rights in methodology. patient's an a have functionally consisting as autologous T regulatory programs of T-Rex pipeline and cell which expanded licensing. Caladrius exclusive as and proprietary our international this or exemplifies or As personalized own by strategy type therapy The
Our partner investment September million since their in continues equity having sites operational in Sanford $X cost to two in cover addition clinical XXXX. made to total Research at Caladrius the
Regenerative also We grants committed the for T-Rex support the The up study. to Institute the has million study. California Medicine to to $XX.X offset key obtained of cost
in collaborators Benaroya Diabetes T-Rex us to of with analysis $XXX,XXX CLBSXX In working Research the T-Rex Benaroya would incurred organization another impact scientists Seattle of and at Research mechanism as Juvenile immune the system their that grant on and Foundation part granted a Mason of their Institute addition, have the better the grant Virginia, study, action. of participants understand study. Benaroya directly to therapies offsets to the of treated we on the This support costs otherwise
results data clinical provide of and into We the contribute expect of understanding the the patients. to participants subsets Benaroya to various to insight
addition look regulatory benefits, distinction. submissions certain into regulatory data the on of and XXX support, key the new the the diabetes priority These first of designations ever key program drug designation advanced designations to research, orphan topline early for user T-Rex fee including and classification, exclusivity in XXXX. FDA they representing month We type application certain credits latter tax a for trial as grant completing all product therapeutic are receive XX in international several X approval. In patients to fast-track follow-up reporting the review to waiver program our EU, forward CLBSXX has FDA fast-track regulatory status, medicinal drug provide
that new us important results become of development the expect We the tool recent to data steps of a will in of X we bolus treatment what in diabetes. will next children our with hope provide the inform type onset an
trial. all have associated less we Moving spending million with the $X forward than T-Rex obligations expect activities complete to of to external
chronic blood or caused of ischemic to ischemia. often due angioplasty to in ischemia focus Heart in serve surgical attack, now blood. vessels drugs, address to technology. to heart on to in vessels use an and for limb acute target that heart to acute date, Turning supply small vessels chronic and of been The critical stent supply and oxygenated to and stroke been disease deficit chronic the tremendous defect CDXX blood large has which congestive strategies a therapy percutaneous the treat impairment the attack with large tissues. in designed the in by clotbusting problems the blood leading to are and our overall There's decrease small of patient Yet contributes the address revascularization failure, the condition. the and no is
responses natural to CDXX blood cells blood microcirculation to disease coronary body's small the induce tissues. tissues. cells of or cells by the tissue CDXX recruitment are preprogrammed vessels of new shown to One to is such been to the blood flow. CDXX in preventing damage all death vessels ischemic the repair improving development of have
the CDXX agreement a license late RfA. treatment Shire to we stage program limb the and two undisclosed rights future refractory treatment upfront CDXX treatment angina comprehensive royalty preclinical, treatment ischemia Phase exchange regulatory angina therapy expand for Shire, from Phase of dataset programs all Phase therapy of for along a refractory microvascular for The are were mainly the a no the platform development Recently, we CMD information as for cell refractory with milestones, We treatment X the to as advancing a for consideration critical proprietary of on currently for our CLBSXX well and for with program CLBSXX coronary product CDXX with CDXX sales. therapy angina dysfunction. filings. the as corresponding an worldwide option of in and exclusive X includes acquisition delighted cell CLBSXX of acquired X, a terms Under study therapy that cell as the cell CDXX has a data clinical
principal we professor became sponsorship merger with program for late to the therapy Losordo, it. When promising studies Needless of which core Baxalta's excited Shire, became Northwestern it given program and with our Medical designed We acquisition. our to X moving investigator as created are this Officer to a especially while available was and Baxalta, to stage late pleased University the as the the Baxter. and consequently and direction were X stage full-time not Dr. knowledge very Phase for our intimate spin Phase the forward complementary Chief program are have out strategic say went Douglas Shire under conducted it therapy. of this Baxter at deprioritized this program be of Upon with the was the
preempted safety reasons prematurely Importantly as decision Phase and is important that including not supported of by for completed randomized sale technical data a any data the Shire. trials study placebo-controlled run three It study program to the Baxalta Baxter's is [offices] Baxter. eventual a X from from X this under partially terminated Phase strategic was the but or that creation of to note
Caladrius combines meta-analysis the a approximately potentially and patient Our program need. from a path recent publication potentially in opportunity to all to therapy bringing to in the registration mortality, forward determine CDXX pain European heart elements and the We diagnoses positive to studies over X for program XXX patients angina for in chest represents treatment XX,XXX months data and FDA critical angina. expeditious most in capacity statistically million and in frequency States the in exercise efficacy look refractory the the large alone measuring to encompassing Journal revealed each commercial year. as people afflicts cell three improvements United to this restrictive with discussions therapy with in the XXX,XXX holding coming This new regulatory
and in studies. added be endpoint following endpoint study patient a a to qualify such consultation laws. CLI conducted is an of dermal prevent This is visits of CMC treatment be can of working monthly means is option and the and time limb or committee. allowing the the Let severe the benefit that pain, ischemia serious for the conditional ulcers step next extremities significantly by of turn option afflicted in The with of than this CLI protocol by are care indication a for and control according Agency Japanese free and choice an arteries The in frame. no an to without primary objective no of can in standard of for consequences these free study CDXX addition defined the recently first it highly randomized extremities clinically early blood in CLBSXX, encompasses a CLBSXX if with eventually country's a by endpoints formulated and of in arm Phase controlled this Pharmaceuticals including the be in or receive patients dosed patients. determined We to flow that historically status of the perspective care PMDA CLI anti-platelet the skin to extending anticoagulants investigators with limb X Japan. employed drugs reached extensive CLI patient X which pharmacotherapy treatment treatment new time XX is technology longer has the potentially show agents, time to the continuous not me lead for adjudication agreement the commercial Critical open and no randomized a quality Those receiving reduces amputation intramuscular limbs successfully Japan intramuscular Japan injection approval improvement and Medical to status will randomized improved obstruction addressed the the CLBSXX label is amputation. feet now our progression proprietary to a which lower two blood of free amputation approved protocol. to pharmacotherapy CLI in dosed strategies administration ischemia. legs. is consecutive for limb. or patient these to regenerative made to of a for standard specifically that study Phase to our CLI will to principally of and sores pharmacotherapy. CLBSXX No Devices that will be relevant flow vasodilators option the multicenter adverse medicine given Patients survival in amputation disease the This spectrum endpoint as used as under should independent to clinical shorter consideration that that on broader study and
Our which confidence conducted show amputation free CDXX in substantial and by claudication status clinical the data trials Japan CLI but cell this and United the also in CLI not approach to survival. four from CLI free in therapy safe improved is and prior supported is only States
three next this Over the to invest expect to X program. approximately support years, million we
this the Japan seek development a to out commercialization advance basis this continue product is the States. to point a entry cardiovascular significant for and United in Review rapid favorable offer market of We the outcomes could in the in which its study indications. with to multiple Japan to applicability underserved potentially to license clinical and broader CLBSXX CDXX across therapy opportunities explore
regeneration program is a CMD. Moving infusion formulation cells to administered specifically treatment a on CDXX potency and CDXX of cardiovascular into is artery treatment proprietary designed as to cells. tissue. repair a CLBSXX coronary and and This uses patented of enhance our for of for the the via
We designed Phase a is cell caused blood the initiate blood to reduce lining the a The vessels microvascular CDXX to vessels heart is of exploratory disease expect arterial in the evaluation with involving damage adverse in assess of are laboratory trial for to heart's the treatment endpoint including a exercise CLBSXX label of CMD physical to events the X which flow events. to damage the of baseline time adverse approximately of or soon ST primary as X increase open The study total that peripheral events dependent exams to Other with CMD. infused adverse inner safety CLBSXX major interventional coronary is plaque depression from tonometry endpoints Fitbit microcirculation. by coronary measurements, cardiac heart. activity serious measured inner and patients devices to innate CLBSXX period. tiny serious ability Phase by of walls microvascular the trial plant CMD clinical adverse endothelial be XX dysfunction arterial consequences investigations, efficacy to and and the by recorded reserve, months change during function, in one-week time the six to we plan will angina, through
are quality the evaluate from use nitroglycerin endpoints for three months this All also accepted will clinical frequency, We six and and regulatory the commonly to health-related defined of of and change study angina end type. life. points baseline in
Heart conducted the to of through As previously SBIR funding. our grant the and announced, nondilutive an of the This by Blood with cover the therapies costs. urgent Health, study CMD generate clinical use from acknowledgment advance to be portfolio The will opportunities and majority such of the approximately treat an our support which $X will of of strategy the develop effective National grant NIH our within innovative Institute need more study pipeline Institutes to Lung and National underscores million product
updating the closing, with and disease. advancing the We we important are continue near three you very cell in In likely will expertise advancement therapy Losordo leader made by long-term in future. forward cardiovascular on Caladrius clinical a extensive look progress these cell and Dr. very therapy value. CDXX that and our treatment we’ve the the excited program a to is promise these in to development CDXX medical to-date believe unique and our provide future be in as cardiovascular expect We indications. programs giving with data across experience we report progress be to notable and encouraged to field
CLBSXX multiple the over pipeline Japan, programs platform myocardial trial the entered forward than targeting Phase ongoing in chronic achieve position Phase advance our for for stronger a to complete enrollment our Moving the clinical months, of initiate with gain Japan XX XX-month to treat refractory the ever technology of angina, expect for multiple XXXX pursue application our grants ischemia and licensing and CLI pursue patients globally. other X of we Phase clinical X CLI XX to regulatory advance milestones. CDXX indications, support the clarity additional treatment study in and all study, next of path forward opportunities patient program Caladrius CMD, in XXX CLBSXX the to follow-up the on in our for new strategy in T-Rex on of X
we believe and medical exciting to with unmet cardiovascular robust autoimmune in disease. technologies clinical a that We promising be development what pipeline needs and advancing address our have
as to have dedicated team work that strong advance and a ready balance programs to need. And innovative effectively experience, and these questions. with We passionate operator, overview to importantly entertain treatment have we're sheet patients option we to bring efficiently programs support and an to we in these
